OncoMatch

OncoMatch/Clinical Trials/NCT06885034

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

Is NCT06885034 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments for gastrointestinal neoplasms.

Phase 1/2RecruitingGlaxoSmithKlineNCT06885034Data as of Sep 2026Location: International · 19 countries

Treatment: Risvutatug Rezetecan · Drug 1 · Drug 2 · Drug 3 · Drug 4This study will check how well a new medicine, Risvutatug rezetecan, (Ris-Rez, also known as GSK5764227) works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Risvutatug RezetecanDrug 1Drug 2Drug 3Drug 4

Cancer type

Colorectal Cancer

Pancreatic Cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Has an ECOG performance status of 0 or 1

Prior therapy

Cannot have received: antibody-drug conjugate with Topoisomerase-1 inhibitor payload

Has received any prior therapy with an Antibody-drug conjugate (ADC) with a Topoisomerase-1 (TOPO1)-inhibitor payload

Lab requirements

Blood counts

adequate organ function

Kidney function

adequate organ function

Liver function

adequate organ function

Has adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • GSK Investigational Site · Los Alamitos, California
  • GSK Investigational Site · Los Angeles, California
  • GSK Investigational Site · Santa Monica, California
  • GSK Investigational Site · Whittier, California
  • GSK Investigational Site · Aurora, Colorado

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT06885034 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior antibody-drug conjugate with Topoisomerase-1 inhibitor payload disqualifies patients from enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify